Robeco Institutional Asset Management B.V. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Robeco Institutional Asset Management B.V. has reduced its stake in Regeneron Pharmaceuticals by 57.6%, now holding 47,708 shares worth approximately $25 million after selling 64,787 shares in the second quarter.
• Regeneron reported a strong quarterly earnings result, with an EPS of $12.89, exceeding estimates by $4.46, and a revenue of $3.68 billion, reflecting a 3.6% increase year-over-year.
• Institutional investors own 83.31% of Regeneron's stock, with several hedge funds significantly increasing their positions in the company during the last financial quarter.

Robeco Institutional Asset Management B.V. lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 57.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,708 shares of the biopharmaceutical company's stock after selling 64,787 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Regeneron Pharmaceuticals were worth $25,047,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of REGN. Nuveen LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $343,764,000. Pacer Advisors Inc. grew its stake in Regeneron Pharmaceuticals by 2,296.9% during the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after acquiring an additional 390,374 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Regeneron Pharmaceuticals by 171.0% during the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock valued at $305,311,000 after acquiring an additional 303,785 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock valued at $724,984,000 after acquiring an additional 174,056 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock valued at $5,966,767,000 after acquiring an additional 121,545 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $600.00 on Friday. The company has a fifty day moving average of $572.12 and a 200 day moving average of $567.94. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,024.36. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $63.59 billion, a P/E ratio of 15.12, a P/E/G ratio of 1.92 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same period in the prior year, the business posted $11.56 EPS. The firm's revenue was up 3.6% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Wall Street Analyst Weigh In

REGN has been the subject of several recent analyst reports. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research note on Monday, August 11th. JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a "buy" rating and a $890.00 target price for the company. Citigroup reiterated a "buy" rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.